A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification

U. Hassan, T. Ghonge, B. Reddy, M. Patel, M. Rappleye, I. Taneja, A. Tanna, R. Healey, N. Manusry, Z. Price, T. Jensen, J. Berger, A. Hasnain, E. Flaugher, S. Liu, B. Davis, J. Kumar, K. White, R. Bashir

Research output: Contribution to journalArticle

Abstract

Sepsis, a potentially life-threatening complication of an infection, has the highest burden of death and medical expenses in hospitals worldwide. Leukocyte count and CD64 expression on neutrophils (nCD64) are known to correlate strongly with improved sensitivity and specificity of sepsis diagnosis at its onset. A major challenge is the lack of a rapid and accurate point-of-care (PoC) device that can perform these measurements from a minute blood sample. Here, we report a PoC microfluidic biochip to enumerate leukocytes and quantify nCD64 levels from 10 μl of whole blood without any manual processing. Biochip measurements have shown excellent correlation with the results from flow cytometer. In clinical studies, we have used PoC biochip to monitor leukocyte counts and nCD64 levels from patients' blood at different times of their stay in the hospital. Furthermore, we have shown the biochip's utility for improved sepsis diagnosis by combining these measurements with electronic medical record (EMR).

Original languageEnglish (US)
Article number15949
JournalNature communications
Volume8
DOIs
StatePublished - Jul 3 2017

Fingerprint

Point-of-Care Systems
Biochips
leukocytes
Microfluidics
stratification
blood
Sepsis
Blood
Leukocyte Count
medical electronics
neutrophils
Electronic Health Records
infectious diseases
guy wires
Electronic medical equipment
death
Length of Stay
Neutrophils
Leukocytes
Sensitivity and Specificity

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification. / Hassan, U.; Ghonge, T.; Reddy, B.; Patel, M.; Rappleye, M.; Taneja, I.; Tanna, A.; Healey, R.; Manusry, N.; Price, Z.; Jensen, T.; Berger, J.; Hasnain, A.; Flaugher, E.; Liu, S.; Davis, B.; Kumar, J.; White, K.; Bashir, R.

In: Nature communications, Vol. 8, 15949, 03.07.2017.

Research output: Contribution to journalArticle

Hassan, U, Ghonge, T, Reddy, B, Patel, M, Rappleye, M, Taneja, I, Tanna, A, Healey, R, Manusry, N, Price, Z, Jensen, T, Berger, J, Hasnain, A, Flaugher, E, Liu, S, Davis, B, Kumar, J, White, K & Bashir, R 2017, 'A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification', Nature communications, vol. 8, 15949. https://doi.org/10.1038/ncomms15949
Hassan, U. ; Ghonge, T. ; Reddy, B. ; Patel, M. ; Rappleye, M. ; Taneja, I. ; Tanna, A. ; Healey, R. ; Manusry, N. ; Price, Z. ; Jensen, T. ; Berger, J. ; Hasnain, A. ; Flaugher, E. ; Liu, S. ; Davis, B. ; Kumar, J. ; White, K. ; Bashir, R. / A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification. In: Nature communications. 2017 ; Vol. 8.
@article{d2b82976d1bb4fda94f3c6c44ab1e247,
title = "A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification",
abstract = "Sepsis, a potentially life-threatening complication of an infection, has the highest burden of death and medical expenses in hospitals worldwide. Leukocyte count and CD64 expression on neutrophils (nCD64) are known to correlate strongly with improved sensitivity and specificity of sepsis diagnosis at its onset. A major challenge is the lack of a rapid and accurate point-of-care (PoC) device that can perform these measurements from a minute blood sample. Here, we report a PoC microfluidic biochip to enumerate leukocytes and quantify nCD64 levels from 10 μl of whole blood without any manual processing. Biochip measurements have shown excellent correlation with the results from flow cytometer. In clinical studies, we have used PoC biochip to monitor leukocyte counts and nCD64 levels from patients' blood at different times of their stay in the hospital. Furthermore, we have shown the biochip's utility for improved sepsis diagnosis by combining these measurements with electronic medical record (EMR).",
author = "U. Hassan and T. Ghonge and B. Reddy and M. Patel and M. Rappleye and I. Taneja and A. Tanna and R. Healey and N. Manusry and Z. Price and T. Jensen and J. Berger and A. Hasnain and E. Flaugher and S. Liu and B. Davis and J. Kumar and K. White and R. Bashir",
year = "2017",
month = "7",
day = "3",
doi = "10.1038/ncomms15949",
language = "English (US)",
volume = "8",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A point-of-care microfluidic biochip for quantification of CD64 expression from whole blood for sepsis stratification

AU - Hassan, U.

AU - Ghonge, T.

AU - Reddy, B.

AU - Patel, M.

AU - Rappleye, M.

AU - Taneja, I.

AU - Tanna, A.

AU - Healey, R.

AU - Manusry, N.

AU - Price, Z.

AU - Jensen, T.

AU - Berger, J.

AU - Hasnain, A.

AU - Flaugher, E.

AU - Liu, S.

AU - Davis, B.

AU - Kumar, J.

AU - White, K.

AU - Bashir, R.

PY - 2017/7/3

Y1 - 2017/7/3

N2 - Sepsis, a potentially life-threatening complication of an infection, has the highest burden of death and medical expenses in hospitals worldwide. Leukocyte count and CD64 expression on neutrophils (nCD64) are known to correlate strongly with improved sensitivity and specificity of sepsis diagnosis at its onset. A major challenge is the lack of a rapid and accurate point-of-care (PoC) device that can perform these measurements from a minute blood sample. Here, we report a PoC microfluidic biochip to enumerate leukocytes and quantify nCD64 levels from 10 μl of whole blood without any manual processing. Biochip measurements have shown excellent correlation with the results from flow cytometer. In clinical studies, we have used PoC biochip to monitor leukocyte counts and nCD64 levels from patients' blood at different times of their stay in the hospital. Furthermore, we have shown the biochip's utility for improved sepsis diagnosis by combining these measurements with electronic medical record (EMR).

AB - Sepsis, a potentially life-threatening complication of an infection, has the highest burden of death and medical expenses in hospitals worldwide. Leukocyte count and CD64 expression on neutrophils (nCD64) are known to correlate strongly with improved sensitivity and specificity of sepsis diagnosis at its onset. A major challenge is the lack of a rapid and accurate point-of-care (PoC) device that can perform these measurements from a minute blood sample. Here, we report a PoC microfluidic biochip to enumerate leukocytes and quantify nCD64 levels from 10 μl of whole blood without any manual processing. Biochip measurements have shown excellent correlation with the results from flow cytometer. In clinical studies, we have used PoC biochip to monitor leukocyte counts and nCD64 levels from patients' blood at different times of their stay in the hospital. Furthermore, we have shown the biochip's utility for improved sepsis diagnosis by combining these measurements with electronic medical record (EMR).

UR - http://www.scopus.com/inward/record.url?scp=85021731172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021731172&partnerID=8YFLogxK

U2 - 10.1038/ncomms15949

DO - 10.1038/ncomms15949

M3 - Article

C2 - 28671185

AN - SCOPUS:85021731172

VL - 8

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 15949

ER -